Skip to main content
. Author manuscript; available in PMC: 2019 Oct 30.
Published in final edited form as: Biol Blood Marrow Transplant. 2016 Jan 28;22(5):869–878. doi: 10.1016/j.bbmt.2015.12.030

Figure 1.

Figure 1.

(A) Treatment schema showing leukapheresis to obtain T cells for expansion, followed by baseline bone marrow biopsy and phenotyping. After expansion ex vivo and arming of ATCs from the patients, 10 × 109 BATs were infused on 2 occasions 1 week apart, followed by a second biopsy to evaluate changes in the BM. Immune testing was performed as indicated at the various time points after SCT. Four patients received BATs booster infusions. (B) (Upper) Daily lymphocyte (Lymph) and ANC counts in 12 patients. (Lower) Daily mean platelet counts. (C) (Upper, Left) CMPC population at 2 weeks post-BATs compared with pre-BATs in all 12 patients. (Upper, Right) Waterfall chart of percent change in CMPC population at 2 weeks post-BATs compared with pre-BATs in patients who remained in remission (uCR) and those who relapsed (REL). (Lower) Absolute percent positive CMPC population in patients who remained in remission (uCR) and those who relapsed (REL).